Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Functional MRI imaging and tomotherapy · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Functional MRI imaging and tomotherapy | PROCEDURE | - |
Inclusion Criteria: * Histologically confirmed glioblastoma multiforme * Ages 18-65 * Karnofsky Performance Scale (KPS) equal to or less than 70 * Minimal neurological deficit * Eligible for concurrent temozolomide chemotherapy Exclusion Criteria: * Prior radiation therapy to hand or neck area, c...
Functional MRI imaging and tomotherapy is an investigational imaging and treatment approach being studied for glioblastoma. It combines magnetic resonance spectroscopic imaging and tumor perfusion assessment with concurrent radiation therapy and temozolomide. The approach is in Phase 1 clinical development for glioblastoma and glioma.
Functional MRI imaging and tomotherapy is being developed by Avalon GloboCare Corp., which trades under the ticker ALBT. The company is conducting clinical research on this imaging and treatment approach for glioblastoma.
Functional MRI imaging and tomotherapy is in Phase 1 clinical development. It is an investigational approach and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed for this imaging and treatment strategy in glioblastoma.
Functional MRI imaging and tomotherapy has one completed clinical trial, NCT00250211, titled "Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide." This Phase 1 study enrolled 26 participants in Canada.
Functional MRI imaging and tomotherapy refers to an approach that incorporates magnetic resonance spectroscopic imaging (MRS) and tumor perfusion assessment alongside radiation therapy. The clinical trial NCT00250211 specifically evaluates MRS and tumor perfusion in glioblastoma patients receiving concurrent radiation and temozolomide.